Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) obtained the drug registration certificate issued by China's National Medical Products Administration for its Empagliflozin tablets in 10 milligrams dosages, a Tuesday Hong Kong bourse filing said.
The drug is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor jointly developed by Boehringer Ingelheim and Eli Lilly. It is used for the treatment of type 2 diabetes in adult patients with symptomatic chronic heart failure.
It works by reducing glucose abortion by the kidneys and by promoting the direct excretion of glucose from the urine.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。